15 | AntigensIBA
03/2022
-
03/2004 |
14 | Proteins (Proteins, Gene)FDA Link
10/2017
-
03/2004 |
13 | AntibodiesIBA
03/2022
-
04/2002 |
8 | LigandsIBA
10/2017
-
03/2005 |
7 | Epithelial Cell Adhesion MoleculeIBA
03/2022
-
03/2004 |
7 | Immunoglobulin FragmentsIBA
01/2019
-
04/2006 |
5 | ErbB Receptors (EGF Receptor)IBA
01/2019
-
03/2005 |
5 | Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
01/2015
-
04/2002 |
5 | Peptides (Polypeptides)IBA
11/2014
-
07/2009 |
5 | Bombesin Receptors (Bombesin Receptor)IBA
10/2013
-
07/2009 |
4 | RadiopharmaceuticalsIBA
01/2021
-
08/2011 |
4 | TNF-Related Apoptosis-Inducing LigandIBA
08/2016
-
03/2004 |
4 | Monoclonal AntibodiesIBA
01/2015
-
03/2005 |
4 | BombesinIBA
10/2013
-
08/2011 |
3 | chondroitin sulfate proteoglycan 4IBA
11/2019
-
01/2016 |
3 | Rituximab (Mabthera)FDA Link
01/2019
-
08/2006 |
3 | VaccinesIBA
10/2018
-
01/2010 |
3 | TNF-Related Apoptosis-Inducing Ligand ReceptorsIBA
02/2016
-
03/2004 |
2 | AzidesIBA
04/2021
-
08/2020 |
2 | Alkynes (Acetylenes)IBA
04/2021
-
08/2020 |
2 | Bispecific AntibodiesIBA
01/2019
-
05/2008 |
2 | Glycoproteins (Glycoprotein)IBA
06/2017
-
08/2008 |
2 | Immunoglobulin G (IgG)IBA
01/2015
-
04/2002 |
2 | temoporfinIBA
10/2014
-
05/2012 |
2 | Immunotoxins (Immunotoxin)IBA
10/2014
-
05/2013 |
2 | Pharmaceutical PreparationsIBA
10/2014
-
07/2009 |
2 | Radioisotopes (Radionuclides)IBA
06/2014
-
08/2012 |
2 | Technetium (Technetium 99m)IBA
10/2013
-
08/2011 |
2 | tricineIBA
10/2013
-
08/2011 |
2 | bombesin (7-14)IBA
10/2013
-
08/2011 |
2 | rimcazoleIBA
09/2013
-
11/2010 |
2 | Death Domain ReceptorsIBA
05/2013
-
02/2007 |
2 | Surface Antigens (Surface Antigen)IBA
05/2013
-
03/2004 |
2 | Bortezomib (Velcade)FDA Link
08/2006
-
04/2006 |
2 | Gefitinib (Iressa)FDA Link
08/2006
-
03/2005 |
1 | Fluorescein (Funduscein)FDA LinkGeneric
03/2022 |
1 | IsotopesIBA
03/2022 |
1 | Adenosine Triphosphate (ATP)IBA
08/2021 |
1 | Adenosine (Adenocard)FDA LinkGeneric
08/2021 |
1 | beta-apocarotenoid-14',13'-dioxygenase (ADO)IBA
08/2021 |
1 | 5'-Nucleotidase (5' Nucleotidase)IBA
08/2021 |
1 | Androgen Receptors (Androgen Receptor)IBA
01/2021 |
1 | enzalutamideIBA
01/2021 |
1 | Viral ProteinsIBA
01/2020 |
1 | Programmed Cell Death 1 ReceptorIBA
11/2019 |
1 | Immune Checkpoint InhibitorsIBA
11/2019 |
1 | blinatumomabIBA
01/2019 |
1 | Erlotinib Hydrochloride (CP 358,774)FDA Link
01/2019 |
1 | durvalumabIBA
01/2018 |
1 | Fluorescein-5-isothiocyanate (FITC)IBA
10/2017 |
1 | Granzymes (Granzyme)IBA
03/2016 |
1 | Estrogens (Estrogen)FDA Link
01/2016 |
1 | ProgesteroneFDA LinkGeneric
01/2016 |
1 | human ERBB2 proteinIBA
01/2016 |
1 | CalreticulinIBA
01/2015 |
1 | Immunoglobulin Fab FragmentsIBA
01/2015 |
1 | Galectins (Galectin)IBA
01/2015 |
1 | Complement System Proteins (Complement)IBA
01/2015 |
1 | Therapeutic UsesIBA
01/2015 |
1 | 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidIBA
11/2014 |
1 | Bleomycin (Blenoxane)FDA LinkGeneric
10/2014 |
1 | 1-phenyl-3,3-dimethyltriazene (PDT)IBA
10/2014 |
1 | chlorinIBA
10/2014 |
1 | Photosensitizing Agents (Photosensitizers)IBA
10/2014 |
1 | Interleukin-17 (Interleukin 17)IBA
09/2014 |
1 | InterleukinsIBA
09/2014 |
1 | Biological ProductsIBA
09/2014 |
1 | CD40 Ligand (CD40L)IBA
04/2014 |